RTW Investments, a life science investment and innovation firm, and QIA, a global investment organization, led a $125m series B1 round in Oricell, a China-based innovative pharmaceutical company, with participation from Qiming Venture Partners and C&D Emerging Industry Equity Investment. “We are thrilled with the momentum our team has built over the last several months and look forward to using this funding to further expand our platform and research. This round reflects our investors’ recognition of Oricell’s ongoing growth and the development of our robust pipeline of ground-breaking therapeutics. We look forward to continuing to help improving the lives of patients in need,” Helen Yang, Oricell Chairman and CEO.